CD163 and infection: Therefore, we hypothesized that the addition of recombinant SRCR1-4 to PAMs would interfere with PRRSV internalization and sequential infection via competitive inhibition for MYH9 binding and thus would interrupt the endogenous CD163 and MYH9 interaction.